Advice
following a full submission:
guanfacine (Intuniv®) is accepted for use within NHS Scotland.
Indication under review: treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Two phase III studies in children and adolescents aged 6 to 17 years with ADHD demonstrated that guanfacine improved the symptoms of ADHD compared with placebo.
Download detailed advice271KB (PDF)
Medicine details
- Medicine name:
- guanfacine hydrochloride (Intuniv)
- SMC ID:
- 1123/16
- Indication:
- treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 February 2016